The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.

Ginger (Zingiber officinale Roscoe) contains phenolic compounds, such as gingerols, shogaols, and zingiberene, recognized for their antioxidant and anti-inflammatory properties, and may act as an adjuvant strategy in the prevention and management of CAD. However, there are no studies in CAD patients evaluating these data.

Inclusion Criteria:

• Both sexes
• Over 18 years of age;
• Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
• Participants who are asymptomatic or have angina limited to functional class III will be considered;
• Patients who have already undergone coronary revascularization and angioplasty may participate;
• the last acute coronary event must have occurred more than one year ago.

Exclusion Criteria:

• Unstable Coronary Artery Disease;
• Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;
• Unstable angina;
• NYHA functional class III or higher;
• Advanced chronic kidney disease (creatinine clearance < 30 ml/min/1.73 m²);
• Individuals with autoimmune diseases.

Participant data will not be public to other research unless necessary.